Third Rock Ventures
Boston, Massachusetts, United StatesFounded 2007
Third Rock Ventures is a leading healthcare venture capital firm focused on advancing disruptive areas of science and medicine to deliver breakthroughs to patients. Founded in 2007 and headquartered in Boston, the firm discovers, launches, and builds early-stage biotechnology and life sciences companies across small-molecule drugs, antibodies, proteins, and cell and gene therapies. Its latest fund, Fund VI, closed at $1.1 billion.
50% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-a (41% of deals). Average disclosed round size is $78.3M (across 109 rounds with reported amounts).
Portfolio
68
Fund Size
$1.1B
Top Stage
Series A
Last 12 Mo
3
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
121 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Merida Biosciences | Series A | $121M | Aug 2026 |
 Flare Therapeutics | Series C | — | Jun 2026 |
 Terremoto Biosciences | Series C | $108M | Apr 2026 |
 Artbio | Series B | $132M | Jul 2025 |
 Corvia | Growth | $55M | Jun 2025 |
 Seaport Therapeutics | Series B | $225M | Oct 2024 |
 Maze Therapeutics | Unknown | $115M | Jan 2024 |
 Asher Bio | Series C | $55M | Jan 2024 |
 Trace Neuroscience | Series A | $101M | Jan 2024 |
| AAsher Biotherapeutics | Series C | $55M | Jan 2024 |
| Seaport Therapeutics | Series A | $325M | Jan 2024 |
| Artbio | Series A | $90M | Dec 2023 |
| Flare Therapeutics | Series B | $123M | Mar 2023 |
 CARGO Therapeutics | Series A | $200M | Mar 2023 |
 Rapport Therapeutics, Inc. | Series B | $150M | Jan 2023 |
 Septerna | Series B | — | Jan 2023 |
| Terremoto Biosciences | Series B | $175M | Jan 2023 |
 Rapport | Series A | $100M | Jan 2023 |
| CARGO Therapeutics | Series A | $200M | Jan 2023 |
| Artbio | Series A | $90M | Jan 2023 |
 MOMA Therapeutics | Series B | $150M | May 2022 |
| CCelsius Therapeutics | Series B | $83M | Mar 2022 |
| CCelsius Therapeutics | Series A | $63M | Mar 2022 |
| Merida Biosciences | Seed | — | Jan 2022 |
| MOMA Therapeutics | Series B | $150M | Jan 2022 |
Page 1 of 5
Top Co-Investors
Casdin Capital24 shared
Cormorant Asset Management16 shared
GV15 shared
ARCH Venture Partners15 shared
The Invus Group, LLC13 shared
RA Capital Management13 shared
Alexandria Venture Investments12 shared
Flagship Pioneering12 shared
Wellington Management11 shared
Foresite Capital11 shared
Boxer Capital10 shared
Polaris Partners9 shared
Nextech Invest Ltd.8 shared
Perceptive Advisors8 shared
Logos Capital8 shared
Alphabet Inc.8 shared
Bessemer Venture Partners7 shared
Fidelity Investments7 shared
Sofinnova Partners7 shared
Eventide Asset Management7 shared
Last updated: 20 October 2026